Compare Novo Nordisk A/S (NVO) vs Teradyne, Inc. (TER) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Teradyne, Inc. — how do they compare? Novo Nordisk A/S trades at $44.88 (market cap $200.69B), while Teradyne, Inc. trades at $381.17 (market cap $55.82B). The key difference: Novo Nordisk A/S is far larger — about 3.6× Teradyne, Inc.'s market cap, and Novo Nordisk A/S pays the higher dividend (3.98%). Which is the better fit depends on your goals.
| NVO | TER | |
|---|---|---|
Market Cap | $200.69B | $55.82B |
Sector | Health | Technology |
52-Week High | $63.98 | $483.84 |
52-Week Low | $35.29 | $112.24 |
Enterprise Value | $215.49B | $55.56B |
Dividend Yield | 3.98% | 0.15% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $45.16, down 3.09% today, with bearish technical signals but strong fundamentals. The stock shows robust profitability with 35.35% net margin and 59.82% ROE, supported by consistent earnings beats. Recent developments include positive pediatric obesity trial results for semaglutide and Wegovy pill launch in Germany. Cash flow remains healthy with $10.81B net inflow in 2025, though 2026 projections show a decline.
NVO presents a mixed outlook with strong fundamental metrics offset by technical weakness and competitive pressures. Investment opportunity lies in the expanding GLP-1 market and pipeline developments, while risks include market share loss to Eli Lilly and failed cardiovascular drug trials. Analyst consensus leans bullish with 57.9% buy ratings, but recent prescription slowdown concerns warrant caution.
Teradyne (TER) trades at $372.06, up 4.21% on the day, with a bullish technical signal and strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Revenue grew to $3.19B in 2025, and net income margin stands at 25.77%. Analyst sentiment is positive, with a consensus price target of $474.78 and no sell ratings among 31 analysts. Recent news highlights surging demand for UltraFLEXplus systems driven by AI and data center growth.
The outlook for TER is favorable, supported by robust AI-driven demand, earnings momentum, and institutional accumulation. Key risks include competitive pressures from KLA and Cohu, reliance on semiconductor cycles, and execution challenges in scaling operations. The stock offers upside potential but remains sensitive to tech sector volatility and macroeconomic conditions affecting capital expenditure trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Teradyne, Inc.
Teradyne provides testing equipment, including automated test equipment for semiconductors, system testing for hard disk drives, circuit boards, and electronics systems and wireless testing for devices. The firm entered the industrial automation market in 2015, into which it sells collaborative and autonomous robots for factory applications. Teradyne serves numerous end markets and geographies directly and indirectly with its products, but its most significant exposure is to semiconductor testing, which made up 71% of 2021 sales. Teradyne serves vertically integrated, fabless, and foundry chipmakers with its equipment.
Read more on TER →
